Attached files
| file | filename |
|---|---|
| 10-K - 10-K - ALEXION PHARMACEUTICALS, INC. | alxn-20201231.htm |
| EX-32.1 - EX-32.1 - ALEXION PHARMACEUTICALS, INC. | alxnex32112312020.htm |
| EX-31.2 - EX-31.2 - ALEXION PHARMACEUTICALS, INC. | alxnex31212312020.htm |
| EX-31.1 - EX-31.1 - ALEXION PHARMACEUTICALS, INC. | alxnex31112312020.htm |
| EX-23.1 - EX-23.1 - ALEXION PHARMACEUTICALS, INC. | alxnex23112312020.htm |
| EX-21.1 - EX-21.1 - ALEXION PHARMACEUTICALS, INC. | alxnex21112312020.htm |
| EX-4.2 - EX-4.2 - ALEXION PHARMACEUTICALS, INC. | alxnex4212312020.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Alexion Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Aradhana Sarin, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: | February 8, 2021 | /s/ ARADHANA SARIN, M.D. | |||||||||
| Executive Vice President and Chief Financial Officer | |||||||||||
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.